

# Protein Phosphatase 2A - Pipeline Review, H2 2020

<https://marketpublishers.com/r/P4BD3B30BE81EN.html>

Date: August 2020

Pages: 50

Price: US\$ 3,500.00 (Single User License)

ID: P4BD3B30BE81EN

## Abstracts

Protein Phosphatase 2A - Pipeline Review, H2 2020

### Summary

According to the recently published report 'Protein Phosphatase 2A - Pipeline Review, H2 2020'; Protein Phosphatase 2A (PP2A or EC 3.1.3.16) pipeline Target constitutes close to 7 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes.

Protein Phosphatase 2A (PP2A or EC 3.1.3.16) - Protein Phosphatase 2A (PP2A) is an enzyme encoded by the PPP2CA gene. PP2A plays important roles in regulation of cell cycle, signal transduction, cell differentiation, and transformation. Its activity is related to several diseases, including neurodegenerative diseases and cancer.

The report 'Protein Phosphatase 2A - Pipeline Review, H2 2020' outlays comprehensive information on the Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 2 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively.

Report covers products from therapy areas Oncology, Central Nervous System, Cardiovascular, Gastrointestinal, Genetic Disorders, Metabolic Disorders,

Ophthalmology and Respiratory which include indications Hepatocellular Carcinoma, Lung Cancer, Ovarian Cancer, Allergic Conjunctivitis, Alzheimer's Disease, Angelman Syndrome, Asthma, Breast Cancer, Carcinoid Tumor, Chronic Lymphocytic Leukemia (CLL), Chronic Obstructive Pulmonary Disease (COPD), Colon Cancer, Crohn's Disease (Regional Enteritis), Depression, Duodenal Cancer, Idiopathic Pulmonary Fibrosis, Insulin Resistance, Ischemic Stroke, Melanoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Myelodysplastic Syndrome, Myocardial Ischemia, Non-Small Cell Lung Cancer, Obesity, Pancreatic Cancer, Pheochromocytoma, Post-Traumatic Stress Disorder (PTSD), Recurrent Glioblastoma Multiforme (GBM), Sarcomas, Septic Shock, Small-Cell Lung Cancer, Soft Tissue Sarcoma, Solid Tumor, Testicular Cancer, Thymoma (Thymic Epithelial Tumor), Triple-Negative Breast Cancer (TNBC), Type 2 Diabetes, Ulcerative Colitis and Uveitis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## Scope

The report provides a snapshot of the global therapeutic landscape for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

The report reviews Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics and enlists all their major and minor projects

The report assesses Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA)

and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Protein Phosphatase 2A (PP2A or EC 3.1.3.16) targeted therapeutics

## **Reasons to Buy**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Protein Phosphatase 2A (PP2A or EC 3.1.3.16)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Protein Phosphatase 2A (PP2A or EC 3.1.3.16) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Overview

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Companies Involved in Therapeutics Development

AbbVie Inc

AstraZeneca Plc

Avalyn Pharma Inc

Boehringer Ingelheim International GmbH

Fratagene Therapeutics Srl

Lead Discovery Center GmbH

Prous Institute for Biomedical Research SA

TopiVert Ltd

Turning Point Therapeutics Inc

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Drug Profiles

bosutinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Inhibit SRC for Friedreich Ataxia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ilorasertib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JRP-890 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nintedanib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Dormant Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Discontinued Products

Proto Oncogene Tyrosine Protein Kinase Src (Proto Oncogene c Src or pp60c src or SRC or EC 2.7.10.2) - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2020  
Number of Products under Development by Therapy Areas, H2 2020  
Number of Products under Development by Indications, H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..1), H2 2020  
Number of Products under Development by Indications, H2 2020 (Contd..2), H2 2020  
Number of Products under Development by Companies, H2 2020  
Products under Development by Companies, H2 2020  
Number of Products under Investigation by Universities/Institutes, H2 2020  
Products under Investigation by Universities/Institutes, H2 2020  
Number of Products by Stage and Mechanism of Actions, H2 2020  
Number of Products by Stage and Route of Administration, H2 2020  
Number of Products by Stage and Molecule Type, H2 2020  
Pipeline by AbbVie Inc, H2 2020  
Pipeline by AstraZeneca Plc, H2 2020  
Pipeline by Avalyn Pharma Inc, H2 2020  
Pipeline by Boehringer Ingelheim International GmbH, H2 2020  
Pipeline by Fratagene Therapeutics Srl, H2 2020  
Pipeline by Lead Discovery Center GmbH, H2 2020  
Pipeline by Prous Institute for Biomedical Research SA, H2 2020  
Pipeline by TopiVert Ltd, H2 2020  
Pipeline by Turning Point Therapeutics Inc, H2 2020  
Dormant Products, H2 2020  
Dormant Products, H2 2020 (Contd..1), H2 2020  
Dormant Products, H2 2020 (Contd..2), H2 2020  
Discontinued Products, H2 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2020

Number of Products under Development by Therapy Areas, H2 2020

Number of Products under Development by Top 10 Indications, H2 2020

Number of Products by Stage and Mechanism of Actions, H2 2020

Number of Products by Routes of Administration, H2 2020

Number of Products by Stage and Routes of Administration, H2 2020

Number of Products by Stage and Molecule Type, H2 2020

### COMPANIES MENTIONED

Lixte Biotechnology Holdings Inc

PEP-Therapy SAS

Re-Pharm Ltd

SupremeCure Pharma Inc

Velacor Therapeutics Pty Ltd

## I would like to order

Product name: Protein Phosphatase 2A - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/P4BD3B30BE81EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P4BD3B30BE81EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970